x

Posted 22 August, 2023

Blue Water Biotech, Inc. appointed new CEO

CEO Change detected for ticker Nasdaq:BWV in a 8-K filed on 22 August, 2023.


  Effective as of August 16, 2023, Joseph Hernandez resigned as Chairman, Chief Executive Officer, and a member of the Board of Directors (the "Board") of Blue Water Biotech, Inc. (the "Company").  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Blue Water Biotech, Inc.
Health Care/Life Sciences • Pharmaceuticals
Blue Water Biotech, Inc. is a biotechnology company, which engages in the research and development of transformational vaccines to prevent infectious diseases worldwide. Its platform includes the BWV Norovirus (NoV) S&P Nanoparticle Versatile Vaccine. Bioengineering the shell (S) and protruding (P) domains of the norovirus capsid protein, polyvalent nanoparticles and polymers/oligomers provide a versatile vaccine platform with wide applications. The company was founded by Joseph Hernandez on October 26, 2018 and is headquartered in Cincinnati, OH.
Market Cap
$4.31M
View Company Details
Blue Water Biotech, Inc. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


Effective as of August 16, 2023, Joseph Hernandez resigned as Chairman, Chief Executive Officer, and a member of the Board of Directors (the "Board") of Blue Water Biotech, Inc. (the "Company"). The Company is reviewing its, and Mr. Hernandez's, respective rights and obligations in connection with this resignation.


Following Mr. Hernandez's resignation, the Board appointed James Sapirstein to serve as Interim Executive Chairman, which appointment shall be effective September 30, 2023. Mr. Sapirstein, an existing member of the Board, will step down as a member of each of the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee upon the effectiveness of his appointment as Interim Executive Chairman. Prior to his appointment, Mr. Sapirstein shall serve as Lead Independent Director of the Board. Mr. Sapirstein shall receive $25,000 per month as compensation for his services as Interim Executive Chairman and, pending such appointment, Lead Independent Director.


Effective August 16, 2023, Board has appointed Jon Garfield, the Company's Chief Financial Officer, to serve as the Company's interim principal executive officer during the pendency of Mr. Sapirstein's appointment. During this period, Mr. Garfield shall have general supervision and direction of the business and affairs of the Company.


The biographical information for Messrs. Garfield and Sapirstein disclosed in the Company's Definitive Proxy Statement on Schedule 14A filed with the SEC on April 26, 2023 is incorporated herein by reference.


No family relationships exist between either Mr. Garfield or Mr. Sapirstein and any other directors or executive officers of the Company. There are no transactions to which the Company is or was a participant and in which either Mr. Garfield or Mr. Sapirstein has a material interest subject to disclosure under Item 404(a) of Regulation S-K.